Prime Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
PRME$4.30-7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows F-
| Year Ended December 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Cash flows used in operating activities: | ||
| Net loss | $(201,142) | $(195,882) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 29,268 | 26,068 |
| Non cash lease expense | 9,698 | 12,355 |
| Depreciation expense | 7,321 | 6,128 |
| Change in fair value of short-term investment — related party | (432) | 484 |
| Amortization of premiums and discount on short-term investments | (1,937) | (3,094) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 4,545 | (15,859) |
| Accounts payable | 996 | (5,257) |
| Accrued expenses and other current liabilities | (1,160) | 1,843 |
| Accrued settlement payment — related party | — | (13,500) |
| Deferred revenue — related party | (4,359) | 70,310 |
| Lease liability | (5,362) | (6,461) |
| Net cash used in operating activities | (162,564) | (122,865) |
| Cash flows (used in) provided by investing activities: | ||
| Maturities of investments | 95,781 | 204,200 |
| Sales of investments — related party | 5,400 | — |
| Purchases of investments | (205,413) | (129,449) |
| Purchases of property and equipment | (4,531) | (7,294) |
| Return (payment) of security deposit | — | 1,000 |
| Net cash (used in) provided by investing activities | (108,763) | 68,457 |
| Cash flows provided by financing activities: | ||
| Proceeds from follow-on offering, net of issuance costs | 138,390 | 132,055 |
| Proceeds from research and development funding liability | 12,000 | 6,000 |
| Net proceeds from stock option exercises | 781 | 103 |
| Proceeds from ESPP offerings | 341 | 837 |
| Proceeds from issuance of common stock under the BMS Securities Purchase Agreement — related party | — | 38,081 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | — | 18,800 |
| Net cash provided by financing activities | 151,512 | 195,876 |
| Net change in cash, cash equivalents, and restricted cash | (119,815) | 141,468 |
| Cash, cash equivalents, and restricted cash at beginning of period | 196,538 | 55,070 |
| Cash, cash equivalents, and restricted cash at end of period | $76,723 | $196,538 |
| Year Ended December 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash, cash equivalents, and restricted cash at end of period | $76,723 | $196,538 |
| Less: restricted cash | 13,691 | 14,062 |
| Total cash, and cash equivalents | $63,032 | $182,476 |
| Supplemental cash flow information: | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $83,757 | $44,935 |
| Decrease in right-of-use assets due to lease termination | $3,120 | $— |
| Increase in right-of-use assets upon settlement with landlord | $10,911 | $— |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $114 | $1,154 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.